Objective: IPF with CNPA is rare, and its clinical manifestations and radiologic features lack specificity compared with other types of pulmonary aspergillosis. This study aims to assess the clinical features of idiopathic pulmonary fibrosis (IPF) with chronic necrotizing pulmonary aspergillosis (CNPA).
Methods: One case of IPF with CNPA is reported and literature review is performed.
Results: The patient had a history of intermittent hemoptysis without history of smoking and alcohol. CT scan of the chest showed bilateral ILD and nodules in the upper lobes of bilateral lungs and middle lobe of the right lung of the patient. CT-guided pulmonary puncture biopsy using microscopy revealed mold hyphae. Based on combined medical history and radiologic findings, the patient was diagnosed with CNPA.
Conclusion: A discriminating pathological feature favors the discovery of aspergillus hyphae in pulmonary tissues, which provides assistance for the early anti-fungal therapy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949565 | PMC |
Virulence
December 2025
Manchester Fungal Infection Group (MFIG), Division of Evolution, Infection, and Genomics, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.
Sulfur metabolism is an essential aspect of fungal physiology and pathogenicity. Fungal sulfur metabolism comprises anabolic and catabolic routes that are not well conserved in mammals, therefore is considered a promising source of prospective novel antifungal targets. To gain insight into sulfur-related metabolism during infection, we used a NanoString custom nCounter-TagSet and compared the expression of 68 key metabolic genes in different murine models of invasive pulmonary aspergillosis, at 3 time-points, and under a variety of conditions.
View Article and Find Full Text PDFBMC Infect Dis
January 2025
Department of Respiratory and Critical Care Medicine, Beijing Youan Hospital, Capital Medical University, 8 Xitoutiao, Youanmenwai, Fengtai District, Beijing, 100069, China.
Background: Invasive pulmonary aspergillosis (IPA) is a common opportunistic infection in patients with severe liver disease (SLD), which increases the mortality of patients. The aim of this study was to evaluate the efficacy and safety of voriconazole for IPA in patients with SLD and explore an optimal antifungal regimen.
Methods: This was a retrospective cohort study of SLD patients diagnosed with proven or probable IPA at Beijing Youan Hospital, Capital Medical University between January 1, 2012 to January 31, 2023.
J Clin Microbiol
January 2025
Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
Invasive pulmonary infections are a significant cause of morbidity and mortality in patients with hematological malignancies and hematopoietic stem cell transplantation (HCT) recipients. A delay in identifying a causative agent may result in late initiation of appropriate treatment and adverse clinical outcomes. We examine the diagnostic utility of PCR-based assays in evaluating invasive pulmonary infections from bronchoalveolar lavage (BAL).
View Article and Find Full Text PDFSci Rep
January 2025
Department of Anesthesiology, Medical Faculty, Heidelberg University, 69120, Heidelberg, Germany.
Invasive infections with Aspergillus fumigatus in ICU patients are linked to high morbidity and mortality. Diagnosing invasive pulmonary aspergillosis (IPA) in non-immunosuppressed patients is difficult, as Aspergillus antigen (galactomannan [GM]) may have other causes. This retrospective study analyzed 160 ICU surgical patients with positive GM in broncho-alveolar lavage fluid (BALF), classifying them based on AspICU criteria for suspected IPA (pIPA) or aspiration.
View Article and Find Full Text PDFPLoS One
January 2025
Asthma and Air Quality Branch, Division of Environmental Health Science and Practice, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
The epidemiology of allergic bronchopulmonary aspergillosis (ABPA) in the United States is not well-described. To estimate national ABPA prevalence among patients with asthma or cystic fibrosis, characterize ABPA testing practices, and describe ABPA clinical features, treatment, and 6-month outcomes. We used the 2016-2022 Merative™ MarketScan® Commercial/Medicare and Multi-State Medicaid Databases to identify cohorts of patients with 1) asthma, 2) cystic fibrosis (CF), and 3) ABPA.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!